INVIMA Regulatory Translation Requirements: The Complete Guide for Drugs and Medical Devices in Colombia

The Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) is Colombia's health regulator, created by Article 245 of Ley 100 de 1993 (INVIMA, Qué hacemos). Colombia's language framework is unusually flexible for a LATAM regulator: Article 49 of Decreto 4725 de 2005 allows technical and scientific device information to be filed "en inglés con traducción oficial al idioma castellano" — English with official Spanish translation (Decreto 4725 de 2005). For drugs, Decreto 677 de 1995 requires foreign documents to be accredited per the Código de Procedimiento Civil, be ≤1 year old, and — if not in Spanish — carry traducción oficial (Arts. 31 §2, 45 §2, 56 §, 67 §1) (Decreto 677 de 1995). Clinical trials run through INVIMA under Resolución 2378 de 2008 with parallel institutional ethics review; Concepto 174/2023 treats official-translator certification plus apostille as cumulative and non-waivable for legal documents (Amavita, Preclinical LATAM). Colombia's device path has the fastest low-risk clock in LATAM: Class I and IIa registrations issue in 2 business days, while Class IIb and III take 90 business days (INVIMA, Dispositivos médicos).

This guide is a complete reference for Spanish (regional-neutral es-419) regulatory translation into the INVIMA framework — drugs and devices, market access, market clearance, and clinical research. It is written for sponsors, CROs, in-house regulatory affairs teams, and CMOs conducting Colombian market entry or maintaining Colombian registrations.

Agency name: Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) — National Institute for Drug and Food Surveillance.

Establishing statute: Article 245 of Ley 100 de 1993 (INVIMA, Qué hacemos). The verbatim statutory text of Art. 245 was not fetched — INVIMA's own institutional page cites it as the creating provision.

Jurisdictional scope: Sanitary inspection, surveillance, and control over medicines, food, medical devices, and biomedical equipment, organized through dedicated directorates (INVIMA, Qué hacemos).

Official website: invima.gov.co

Headquarters: Not stated in fetched sources.

Adjacent bodies you must coordinate with

Data-source note: Colombia has no ClinRegs country profile, so clinical-trial granularity in this guide comes directly from Resolución 2378/2008, Decreto 677/1995, Decreto 4725/2005, and the Amavita library.

Colombian submissions do not go to INVIMA alone. A properly-executed Colombian trial or registration requires coordinated filings across INVIMA (regulatory), the site CEI (ethics), CNPMDM plus MinSalud (economic and pricing), and the Ministerio de Relaciones Exteriores (legalization chain and translator recognition). Vendors who treat INVIMA as a single-agency submission produce packages that fail cross-body review.

Colombia's official language is castellano (Spanish), and INVIMA reviews dossiers in es-419 (regional-neutral Spanish) — not castellano peninsular, not Mexican Spanish. The language rule differs sharply between drugs and devices, and vendors who don't segment the two frameworks either over-translate (wasting cost) or under-translate (triggering RFIs).

Drugs — Decreto 677 de 1995

(Decreto 677 de 1995)

• Arts. 31 §2, 45 §2, 56 §, 67 §1: foreign documents must be accredited per the Código de Procedimiento Civil, must be issued no more than one year before the application, and, if not in Spanish, "requerirá traducción oficial" (require official translation).
• Art. 74: labels of imported drugs may be accepted as issued in the country of origin *provided the importer's name, composition, storage conditions and registro number appear in Spanish*.
• Arts. 81 and 84 (the latter for cosmetics): Spanish required.

Decreto 677/1995 has no Article 49 equivalent — no explicit English-technical-content concession for drugs.

Devices — Decreto 4725 de 2005

(Decreto 4725 de 2005)

• Art. 49: "La información técnica o científica podrá ser allegada en inglés con traducción oficial al idioma castellano" — technical/scientific information may be filed in English with official Spanish translation. This is the single most consequential language provision in the Colombian device framework, and the most permissive technical-content rule among the six LATAM regulators covered in this guide series.
• Art. 44: foreign official documents must be authenticated by the Colombian consul plus the Ministerio de Relaciones Exteriores, or apostilled, and "cuando no estén en idioma castellano requerirán traducción oficial".
• Art. 18(h): Spanish operation and maintenance manuals.
• Art. 24(c)(5): manuals in the original language and Spanish.
• Art. 54: minimum label information in Spanish.
• Art. 56: insert in Spanish.
• Art. 57: additional Spanish label for imports.

The practical band — Circular Externa 5000-0001-22

Amavita records INVIMA as tolerating English for technical annexes, with an official translator required for the legal tier (Amavita, Which Regulators Accept English Dossiers). Circular Externa 5000-0001-22 (August 2022), Section II.1 endorses full-English technical dossiers with a Spanish summary for device biocompatibility, sterility, stability, risk analyses, clinical studies, and electrical-safety reports, with graphs and diagrams requiring no translation at all (Amavita, Preclinical LATAM). The INVIMA device product page independently lists Circular 5000-001-2022 among the applicable device norms (INVIMA, Dispositivos médicos).

The biologics gap

Decreto 1782/2014 governs biological drugs, and Amavita's analysis notes it contains no language article (Amavita, Preclinical LATAM). Biologics filings default to the general Decreto 677/1995 foreign-document rule.

Register and terminology expectations

• All dossiers are reviewed in es-419 regional-neutral Spanish — not castellano peninsular and not Mexican Spanish (Amavita, Regulatory Language Infrastructure).
• Adverse event terminology must align with MedDRA.
• INFLESZ ≥55 is the operational readability threshold for Spanish ICFs, anchored in Resolución 2378/2008 (Amavita, INFLESZ Threshold).

Who qualifies as traductor oficial

A traductor oficial is recognized by the Ministerio de Relaciones Exteriores and holds ministerial certification. Concepto 174/2023 clarifies that official-translator certification plus apostille are cumulative and non-waivable for legal documents — vendors cannot substitute one for the other (Amavita, Sworn vs Certified; Amavita, Preclinical LATAM).

Apostille sequencing

The correct order is original → apostille (or consular authentication) → sworn translation → binding. Vendors who sworn-translate before apostille produce apostilles that do not attach to a valid Spanish version, forcing re-execution. Sworn translation applies only to documents that create or prove legal standing — powers of attorney, corporate authorizations, health-authority certificates. Sworn-translating technical CMC content wastes 30-70% of translation cost (Amavita, Costly Translation Mistakes).

The ≤1-year age rule — a documented risk

Colombia's ≤1-year age rule for foreign drug documents (Arts. 31 §2, 45 §2, 56 §, 67 §1 Decreto 677/1995) is one of the two hardest "stale-document" rules in LATAM alongside Peru's 2-year expiry (Decreto 677). A foreign-authority certificate translated on day 350 and submitted on day 400 is invalid — the translation quality is irrelevant. Amavita's seventh QC gate — Document Currency — verifies that each foreign instrument is within Colombia's 1-year window at the moment of submission, not the moment of translation (Amavita, Translation QC).

Colombia's preclinical answer is asymmetric: the drug pathway and the device pathway do not treat the same document the same way, and the legal-document rule is stricter than either.

D.1 Do we have to translate every page of the preclinical stack?

Rarely. Circular 5000-0001-22 §II.1 contains the concession sponsors most often miss: graphs and diagrams require no translation. Figures, chromatograms, dose-response curves, histopathology plates, and schematic diagrams inside a study report may stay exactly as generated. Combined with INVIMA's acceptance of English technical evidence with a Spanish summary layer, that removes most of the non-clinical stack from the translation budget.

The device-vs-drug asymmetry matters. For drugs, INVIMA reviews an English CTD Module 4 with a Spanish overview. For devices, the technical file can travel further in English, but the labelling, IFU, and any patient-facing content are held to Spanish without exception — and device dossiers more frequently pull in foreign legal instruments (manufacturer declarations, ISO certificates, authorized-representative appointments) that fall into the strict tier below.

D.2 If translation IS required — is it text-only, or does it require DTP?

For legal documents, text-only but cumulative. Concepto 174/2023 establishes that the requirements for foreign legal documents are cumulative and non-waivable: apostille and official translation and, where applicable, consular legalization — one does not substitute for another. Sponsors who apostille and stop, or translate and stop, are rejected on form rather than substance.

DTP applies to device labelling, IFU, and any figure-bearing Spanish summary where the graph is retained in English under §II.1 but its caption and legend are rendered in Spanish — a caption-layer DTP task that is cheaper than full artwork rebuild but is not text-only.

D.3 If translation is NOT required — what substitutes for it?

A Spanish non-clinical summary per study, a Spanish caption and legend layer over retained English figures, and a Spanish cross-reference index into the English technical file. For devices, a Spanish essential-principles conformity table citing untranslated test reports by number.

The two regulatory pathways trigger different translation obligations

Every LATAM regulator operates two related but separate regulatory pathways for a sponsor's product: (1) clinical-trial authorization, which is what allows the investigational product to enter a clinical study on the sponsor's timeline; and (2) market-access / sanitary registration, which is what allows the commercial product to be sold. These pathways trigger different translation obligations. The most common sponsor error is applying a market-access translation obligation (device IFU, primary label, secondary packaging) to a clinical-trial dossier where that obligation is not yet in force.

Pathway 1 — clinical-trial authorization

• Protocol, IB, and ICF must be in Spanish for institutional ethics committee approval and INVIMA under Resolución 2378 de 2008.
• Foreign health-authority letters as traductor oficial + apostille per Concepto 174/2023 (cumulative and non-waivable).

Pathway 2 — market-access / sanitary registration

• Full Spanish device IFU and labelling per Decreto 4725 de 2005 labelling rules (DTP required).
• Drug labelling in full Spanish per Decreto 677 de 1995.
• Note: Art. 46 Decreto 4725/2005 requires the device to be placed on market within 36 months of registration — sponsors who file speculatively risk lapse and re-submission.

For each document class in this guide's consolidated preclinical instruction table below, check which pathway it is scoped to before authorizing translation. A document that requires DTP-scope translation for market registration may require only text-flow translation — or no translation at all — for clinical-trial authorization.

D.4 Consolidated preclinical instruction table

Where the preclinical translation risk actually sits

In the cumulative rule, not the study reports. The §II.1 figure concession is real money saved; Concepto 174/2023 is real time lost when a sponsor treats apostille and official translation as alternatives. The device-vs-drug asymmetry is the second trap: a translation scope copied from a drug filing under-covers a device filing's labelling surface.

D1. Drugs — Market access (pricing, reimbursement)

Colombia's price regulation sits with the Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos (CNPMDM), operating through circulares:

• Circular 21 de 2026: new SISMED technical annex and reporting content
• Circular 22 de 2026: Listado de Precios Máximos de Venta by commercial presentation; Art. 4 orders publication of the list; Art. 8 sets the prices' entry into force on 19 August 2026

Stakeholders may file observations on the list through a form, restricted exclusively to that list (MinSalud).

Translation load for market access

Documents specific to a pricing/reimbursement submission — economic dossiers, reference-country comparators, budget-impact analyses — and the statutory decision timeline are not published on the MinSalud page. The general Decreto 677/1995 foreign-document rule (official translation, ≤1 year old) would apply to any foreign price-reference documentation (Decreto 677).

D2. Drugs — Regulatory submissions for market clearance

Modalities (Art. 14 Decreto 677/1995): fabricar y vender, importar y vender, plus other listed modalities (Decreto 677).

Two product classes (Art. 19): products whose actives are in the normas farmacológicas vs new drugs (Decreto 677).

Three evaluations (Art. 20): farmacológica, farmacéutica, and legal; Art. 26 requires all three (pharmacological + pharmaceutical + legal) for new drugs (Decreto 677).

Abbreviated route (Art. 27 §1): available where the product is registered in two or more reference countries (Decreto 677).

Statutory clocks (Decreto 677/1995) (Decreto 677):

Documents requiring translation

• Foreign certificates and legal documents with traducción oficial and ≤1-year age (Arts. 31 §2, 45 §2, 56 §, 67 §1 Decreto 677/1995)
• Spanish label elements for imported drugs — importer name, composition, storage conditions, registro number (Art. 74)
• CPPs and GMP certificates: traducción oficial required
• CTD legal tier: full Spanish
• CTD technical modules: practical band is English with Spanish summary, but Decreto 677/1995 lacks the Art. 49 device concession — for drug technical modules, official translation is the safe default

Empirical timelines

No verified empirical INVIMA drug market-clearance clock was found in fetched sources.

Biologics extras

Decreto 1782/2014 governs biologics but contains no language article (Amavita, Preclinical LATAM) — biologics default to the Decreto 677/1995 foreign-document rule. Pediatric-specific and orphan-specific translation requirements are not enumerated in fetched sources.

D3. Drugs — Clinical research trial submissions

Authorizing agency: INVIMA. Art. 4 of Resolución 2378 de 2008 requires every drug research project in humans to be registered with INVIMA; Art. 5 prohibits starting a project without INVIMA approval or prior visto bueno; Art. 4 §3 requires attaching a copy of the INVIMA project registration when requesting project approval (Resolución 2378 de 2008).

Legal identity of the instrument: Resolución 002378 of 25 June 2008, Ministerio de la Protección Social, "Por la cual se adoptan las Buenas Prácticas Clínicas para las instituciones que conducen investigación con medicamentos en seres humanos", published in Diario Oficial 47.033 on 27 June 2008 (Resolución 2378).

GCP certification regime

• Art. 3: INVIMA verifies GCP compliance and issues a certificate, valid five years
• Art. 8: required a Plan Gradual de Cumplimiento within six months of issuance, attached to every research project and subject to INVIMA verification
• Art. 10: gave institutions two years to obtain GCP certification
• Art. 4 §2: requires Sistema Único de Habilitación certification of conditions (Resolución 2378)

Ethics framework

Dual — INVIMA plus the Institutional Ethics Committee under Art. 7 and its paragraphs. The CEI evaluates the project, the informed-consent form, known drug information including unexpected AE reports, and all planned recruitment advertising (Art. 7 §1). Projects from institutions without their own committee route to another institution's committee (Art. 7 §2) (Resolución 2378).

Documents requiring translation

• ICF: Spanish (es-419) required for CEI approval
• Protocol and Investigator's Brochure (IB / Manual del Investigador) for medicamentos clinical-study authorization filings: Spanish and English under Guía ASS-RSA-GU030 (now ACOM-INS110), as clarified by INVIMA derecho de petición radicado 20261299661 — see the subsection below
• Foreign clinical-trial authorizations used for reliance: apostilled/consular-authenticated + traducción oficial if not in Spanish
• ICF must clear the INFLESZ ≥55 readability threshold or CEI escalates (Amavita, INFLESZ Threshold)

Clinical-study authorization language — medicamentos (GU030 / ACOM-INS110) — Sep 2026 clarification

Direct answer (medicamentos path only). For Colombian drug clinical-study authorization filings under Guía ASS-RSA-GU030 (now ACOM-INS110 — Instructivo para la presentación de protocolos de estudios clínicos con medicamentos), INVIMA's September 2026 reply to a bioaccess® derecho de petición, radicado 20261299661 (Grupo de Investigación Clínica, Dirección de Medicamentos y Productos Biológicos; signed María Isabel Vargas Velasco), clarifies:

1. The Protocol and the Investigator's Brochure (Manual del Investigador) must be submitted in Spanish and English.
2. Relevant preclinical/clinical product information is treated as consolidated in the IB; because the IB must be ES+EN, that consolidated content must be available in both languages inside the IB.
3. That is different from a general duty to fully translate into Spanish every underlying technical source report, individual study, or publication — GU030/ACOM-INS110 does not impose that blanket duty.
4. INVIMA states its 26 August 2026 communication must not be read as creating a general obligation to translate all supporting technical/source reports into Spanish.
5. INVIMA may still issue complementary information requests case-by-case on a specific expediente.
6. The reply is expressly a non-binding criterio orientador (Ley 1755 art. 28 framing) — not a binding resolution and not immunity from requerimientos.

Devices: Do not cite radicado 20261299661 as authority for device clinical investigations. Device clinical-investigation language follows the competent devices instructivo (e.g. the Resolución 4002/2007 pathway and current Dirección de Dispositivos Médicos instruments) and may differ.

Amavita Sciences™ scoping note (no rates): Default translation scope for medicamentos clinical-auth dossiers: Protocol + IB, ES+EN. Full source-report Spanish packages are optional / risk-based, not a GU030 mandate — contingency if INVIMA requires them on that expediente.

Amendments

The resolution's Technical Annex glossary defines "Enmienda al proyecto" as a written description of change(s) or formal clarification of a project. Art. 6 empowers INVIMA to interrupt an investigation at any time or require project modifications, on grounds (a) alteration of authorization conditions, (b) GCP non-compliance, (c) protection of trial subjects, (d) protection of public health. Art. 6 § requires communicating favourable or unfavourable results whether the investigation completes or is abandoned. The resolution as fetched sets no amendment classification, no amendment deadline, and no amendment language rule (Resolución 2378).

Statutory timelines

Resolución 2378/2008 as fetched states no day-count for INVIMA project approval. The periods it does fix are:

• Six months (compliance plan, Art. 8)
• Two years (GCP certification, Art. 10)
• Five years (certificate validity, Art. 3 §)
• ≤10 business days to schedule subsequent evaluation visits after an evaluator's initial visit (Technical Annex, Ch. II, §1.1(c))

Amavita's amendment dataset supplies the operational figures: statutory 60 business days with a typical 45 business days for amendment handling under Resolución 2378/2008 (Amavita, Amendment Cascade).

PV report language

Resolución 2378/2008 as fetched sets no adverse-event language rule and no reporting day-count. Adverse-event information is, however, part of what the Institutional Ethics Committee must evaluate (Art. 7 §1) (Resolución 2378).

E1. Devices — Market access

The CNPMDM mandate covers dispositivos médicos as well as medicines by its own name, and its 2026 circulars govern the maximum-sale-price listing regime (MinSalud). Device-specific reimbursement dossiers, hospital procurement/tender translation requirements, and their timelines are not enumerated in fetched sources.

A commercial deadline that functions as an access constraint: Art. 46 Decreto 4725/2005 requires the device to be placed on the market within 36 months of registration (Decreto 4725). Vendors who obtain registro sanitario speculatively — without imminent commercial launch — risk registration lapse and re-submission.

E2. Devices — Regulatory submissions for market clearance

Classification: INVIMA states that device classification rests on potential risks from use and failure, considering duration of body contact, degree of invasiveness, and local vs systemic effect, following the rules of Article 7 of Decreto 4725 de 2005 (INVIMA, Dispositivos médicos). The classes are I, IIa, IIb, and III.

Note: Colombia's four-class scale (I/IIa/IIb/III) is not identical to Mexico's three-class scale (I/II/III) or Brazil's four-class scale using Roman numerals I–IV. Vendors submitting the same device in multiple LATAM markets must reclassify per jurisdiction.

Pathways (Decreto 4725/2005) (Decreto 4725):

• Art. 16: registro sanitario for non-controlled Class IIb/III devices
• Art. 17: automatic registro for Class I / IIa
• Art. 23: permiso de comercialización for controlled-technology biomedical equipment
• Art. 27: modalities

Statutory and published clocks

Colombia's Class I/IIa 2-business-day clock is the fastest low-risk-device path among the six LATAM regulators covered in this guide series.

Documentation by class

INVIMA's Formato Único de Diligenciamiento de Dispositivos Médicos requires:

• Class I devices: numerals 1–14, 17, and 18
• Class IIa: 1–18
• Class IIb / III: 1–20 as applicable
• Biomedical equipment Class I: 1–15, 18–19
• Biomedical equipment Class IIa: 1–19
• Biomedical equipment Class IIb/III uses the permiso de comercialización route via form code ASS-RSA-FM007 (INVIMA device page)

Reference-country homologation — Decreto 3275 de 2009

For products from the European Community, United States, Canada, Japan, Australia, or mutual-recognition partners:

• Class I / IIa: technical studies and analytical verifications, sterilization method, and disposal method are homologated
• Class IIb: clinical studies are additionally homologated (INVIMA device page)

Per-class translated documents

• Spanish operation/maintenance manuals (Art. 18(h))
• Manuals in origin language and Spanish (Art. 24(c)(5))
• Spanish label minimum content (Art. 54)
• Spanish insert (Art. 56)
• Additional Spanish label for imports (Art. 57)
• Art. 49 English-plus-official-Spanish-translation concession for technical/scientific information (Decreto 4725)

Empirical device timelines

Amavita's Class III cardiovascular case gives 32 business days (~7 weeks) total added delay for an IFU cross-reference RFI (see Section F) (Amavita, RFI Anatomy).

IVD / SaMD / combination-product extras

Not enumerated in fetched sources. The INVIMA device page lists additional applicable norms including Resolución 4816 de 2008, Resolución 4002 de 2007, Resolución 0214 de 2022, Resolución 5491 de 2017, Resolución 2968 de 2015, Resolución 4396 de 2008, Decreto 1030 de 2007, Decreto 3275 de 2009, and Decreto 582 de 2017 (INVIMA device page) — vendors bringing IVD or SaMD products should confirm current INVIMA classification guidance for those subcategories.

E3. Devices — Clinical research trial submissions

Resolución 2378/2008 is by its own title limited to research with medicines ("investigación con medicamentos en seres humanos") (Resolución 2378). A distinct device-trial instrument is listed among INVIMA's device norms — Resolución 4002 de 2 de noviembre de 2007 — but its content was not fetched. Vendors running a Colombian device trial should confirm the current device-trial pathway, document set, first-in-human vs pivotal vs post-market distinctions, and timelines directly with INVIMA. The ethics-committee requirement for device research (whether the Art. 7 CEI mandate extends by analogy from Resolución 2378/2008 or whether Resolución 4002/2007 sets a distinct rule) is not enumerated in fetched sources.

Documented INVIMA case: a Class III cardiovascular device IFU where cross-reference drift (Sección 6.3 vs 6.4) triggered a *requerimiento*. Sequence:

1. Submission
2. Requerimiento citing IFU section-numbering inconsistency
3. Response window 30 business days; sponsor responded on day 18
4. Re-review added 14 business days
5. Total delay: 32 business days (~7 weeks)

The case cites Decreto 4725/2005 as the authority permitting English technical content with official Spanish translation (Amavita, RFI Anatomy).

The six recurring defect classes (INVIMA-applicable)

Structural-inventory and cross-reference defects are one of the six defect classes Amavita tracks across LATAM regulators (Amavita, Amendment Cascade):

1. Numeric integrity — decimal separators, unit conversions
2. Negation preservation — "not less than" ↔ "at least" flips
3. Readability below INFLESZ 55 — ICF register mismatch (Resolución 2378/2008 anchor)
4. Terminology inconsistency — MedDRA drift within the same dossier
5. Structural inventory — missing sections, cross-reference drift (the Class III cardiovascular case)
6. Jurisdictional adaptation — castellano peninsular delivered where es-419 required

The seventh defect class Amavita has added — Document Currency — is especially consequential for INVIMA drug submissions because of the ≤1-year foreign-document age rule.

For the full case-by-case analysis, see the six LATAM regulator rejections deconstructed blog post.

Where an item is marked n.a., that timeline is not stated in the fetched primary sources.

• Circular 21 de 2026 — new SISMED technical annex and reporting content (MinSalud)
• Circular 22 de 2026 — Listado de Precios Máximos de Venta; Art. 4 publication, Art. 8 entry into force 19 August 2026 (MinSalud)
• Circular Externa 5000-0001-22 (August 2022) — Amavita reads Section II.1 as endorsing full-English technical dossiers with Spanish summary for device technical reports; INVIMA lists it as "Circular 5000-001-2022" in its device norms (Amavita, Preclinical LATAM; INVIMA device page)
• Concepto 174/2023 — official-translator certification by the Ministerio de Relaciones Exteriores plus apostille treated as cumulative and non-waivable for legal documents (Amavita, Preclinical LATAM)
• Resolución 0214 de 2022 appears in INVIMA's current device norm list (INVIMA device page)
• Context — Argentina's ANMAT has adopted ICH E6(R3) via Disposición 7516/2025 effective 1 December 2025 (Boletín Oficial). INVIMA has not yet adopted E6(R3); Colombia's GCP framework remains anchored in Resolución 2378/2008. Sponsors running multi-country LATAM trials should track this standard-alignment gap.

• Which Regulators Accept English Dossiers — INVIMA band: English tolerated for technical annexes, official translator for legal tier
• Preclinical Translation Requirements — 9 LATAM Regulators — Circular Externa 5000-0001-22 §II.1, Decreto 4725 Art. 49, Concepto 174/2023, biologics language-article absence
• RFI Anatomy — Class III cardiovascular IFU cross-reference drift, +32 business days
• Amendment Cascade — Resolución 2378/2008 amendment path, 60 statutory / 45 typical business days
• INFLESZ Threshold — Resolución 2378/2008 as the Colombian ICF-readability anchor
• Sworn vs Certified Translation — traductor oficial with foreign-ministry recognition
• Regulatory Language Infrastructure — es-419 delivery variant
• Translation QC for Regulatory Dossiers — seven QC gates including Document Currency
• Costly Translation Mistakes — apostille sequencing
• Three Bands of LATAM Regulatory Translation — 12-regulator scope framing